Table 1.
Physiological parameters of uninephrectomized (UNX), UNX and deoxycorticosterone-treated (DOCA), UNX + suberoylanilide hydroxamic acid (SAHA) and DOCA + SAHA-treated rats
| Parameter | UNX (4 weeks) | UNX+SAHA (4 weeks) | DOCA (4 weeks) | DOCA+SAHA (4 weeks) |
|---|---|---|---|---|
| Initial body weights (g) | 358 ± 5 (n= 6) | 346 ± 15 (n= 6) | 353 ± 6 (n= 6) | 339 ± 8 (n= 6) |
| Final body weights (g) | 441 ± 6 (n= 6) | 353 ± 12# (n= 6) | 351 ± 8# (n= 6) | 351 ± 12# (n= 6) |
| Daily food intake (g) | 31 ± 3.2 (n= 6) | 21.3 ± 4 (n= 6) | 26.6 ± 4 (n= 6) | 24.2 ± 4 (n= 6) |
| Daily water intake (g) | 62.7 ± 10 (n= 6) | 56.4 ± 7 (n= 6) | 155.9 ± 33.2# (n= 6) | 192 ± 35# (n= 6) |
| Systolic blood pressure (mmHg) 0 weeks | 107 ± 1.3 (n= 6) | 108 ± 3.1 (n= 6) | 108 ± 3.1 (n= 6) | 113 ± 1.6 (n= 6) |
| Systolic blood pressure (mmHg) 2 weeks | 128 ± 0.7 (n= 6) | 126 ± 6.9 (n= 6) | 176 ± 7.3# (n= 6) | 143 ± 4.5* (n= 6) |
| Systolic blood pressure (mmHg) 4 weeks | 135 ± 1.7 (n= 6) | 129 ± 3.0 (n= 6) | 186 ± 3.6# (n= 6) | 160 ± 1.6* (n= 6) |
| Diastolic stiffness constant (κ) | 20.3 ± 0.8 (n= 6) | 17.0 ± 0.6 (n= 6) | 32.3 ± 1.7# (n= 6) | 24.8 ± 0.9* (n= 6) |
| LV+septum (mg·g−1 body wt) | 1.7 ± 0.07 (n= 6) | 2.1 ± 0.04 (n= 6) | 3.1 ± 0.1# (n= 6) | 2.4 ± 0.07* (n= 6) |
| RV (mg·g−1 body wt) | 0.30 ± 0.03 (n= 6) | 0.38 ± 0.01 (n= 6) | 0.51 ± 0.04# (n= 6) | 0.42 ± 0.03* (n= 6) |
| Liver (mg·g−1 body wt) | 34.8 ± 0.9 (n= 6) | 35.1 ± 1.5 (n= 6) | 52.4 ± 1.9# (n= 6) | 48.9 ± 2.1 (n= 6) |
| Spleen (mg·g−1 body wt) | 2.9 ± 0.2 (n= 6) | 3.4 ± 0.3 (n= 6) | 4.4 ± 0.1# (n= 6) | 3.8 ± 0.5 (n= 6) |
| Kidneys (mg·g−1 body wt) | 4.3 ± 0.1 (n= 6) | 4.2 ± 0.2 (n= 6) | 8.5 ± 0.2# (n= 6) | 8.4 ± 0.6 (n= 6) |
| Resting membrane potential (mV) | −71.1 ± 3.7 (n= 8) | −63.0 ± 0.9# (n= 4) | −74.3 ± 1.7 (n= 9) | −61.3 ± 3.5* (n= 10) |
| Action potential amplitude (mV) | 83.8 ± 5.3 (n= 8) | 56.7 ± 3.2# (n= 4) | 81.1 ± 4.5 (n= 9) | 55.1 ± 3.7* (n= 10) |
| Action potential duration at 20% (ms) | 6.8 ± 1.1 (n= 8) | 11.8 ± 1.6# (n= 4) | 24.5 ± 4.1# (n= 9) | 16.7 ± 1.2* (n= 10) |
| Action potential duration at 50% (ms) | 16.4 ± 2.0 (n= 8) | 22.3 ± 5.8 (n= 4) | 40.5 ± 5.9# (n= 9) | 31.3 ± 2.9# (n= 10) |
| Action potential duration at 90% (ms) | 34.4 ± 3.5 (n= 8) | 44.2 ± 8.5 (n= 4) | 84.2 ± 8.1# (n= 9) | 62.3 ± 5.1* (n= 10) |
| Force of contraction (mN) | 1.1 ± 0.4 (n= 8) | 0.8 ± 0.1 (n= 4) | 0.34 ± 0.01 (n= 9) | 3.8 ± 1.0* (n= 10) |
| Plasma malondialdehyde (MDA) concentration (µmol·L−1) | 19.7 ± 0.7 (n= 5) | 21.0 ± 0.8 (n= 5) | 27.3 ± 0.8* (n= 5) | 24.7 ± 0.3* (n= 5) |
#
P < 0.05 vs. UNX;
*
P < 0.05 vs. DOCA. LV mass calculated according to Litwin et al. (1994).
Values are mean ± SEM; number of experiments in parentheses.
LV, left ventricle; RV, right ventricle.